Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autobio Diagnostics CoSHSE:603658 -2.18%95 EBITDA Margin % is 26.97% as of Jun. 2026, which is 34% below its 10-year median of 40.82. GuruFocus rates SHSE:603658 with a GF Score™ of 95/100 and a GF Value™ of ¥40.43 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Autobio Diagnostics Co ranks better than 86.98% on this metric.
Autobio Diagnostics Co (SHSE:603658) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Autobio Diagnostics Co EBITDA Margin % Related Terms
Autobio Diagnostics Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Autobio Diagnostics Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603658 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Autobio Diagnostics Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autobio Diagnostics Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Autobio Diagnostics Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autobio Diagnostics Co (SHSE:603658) has a EBITDA Margin % of 26.97% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Autobio Diagnostics Co and its competitors. This is 34% below median its historical median of 40.82. Over the past decade, Autobio Diagnostics Co's EBITDA Margin % has ranged from 27.00 to 49.20. According to the industry distribution chart, Autobio Diagnostics Co ranks #106 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 13%.
Is Autobio Diagnostics Co's EBITDA Margin % too high?
Autobio Diagnostics Co's current EBITDA Margin % of 26.97% is 34% below median its 10-year median of 40.82. Over the past 10 years, this metric has ranged from a low of 27.00 to a high of 49.20. The Medical Devices & Instruments industry median EBITDA Margin % is 8.08. Autobio Diagnostics Co's value of 26.97% is 233.8% above this industry median. Based on the distribution chart, Autobio Diagnostics Co ranks #106 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Autobio Diagnostics Co ranks #106 out of 814 companies for EBITDA Margin %. This places Autobio Diagnostics Co in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 8.08. Autobio Diagnostics Co's value of 26.97% is 233.8% above this benchmark. Historically, Autobio Diagnostics Co's own EBITDA Margin % has ranged from 27.00 to 49.20 over the past decade. While the company's 10-year median is 40.82 vs. the industry median of 8.08, Autobio Diagnostics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 8.08, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autobio Diagnostics Co's current EBITDA Margin % of 26.97% is 233.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Autobio Diagnostics Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 8.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autobio Diagnostics Co's current EBITDA Margin % is 26.97%, which is 34% below median its own 10-year median of 40.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.43, compared to a current price of ¥32.68 — trading 19.2% below its estimated fair value. The current EBITDA Margin % is 26.97%, which is 34% below median its 10-year median of 40.82 and 233.8% above the Medical Devices & Instruments industry median of 8.08. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current EBITDA Margin % is 26.97% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?
Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued.
The current stock price of ¥32.68 is trading 19.2% below its estimated GF Value™ of ¥40.43.
GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.
Key valuation signals for SHSE:603658:
EBITDA Margin %: 26.97% (34% below median its 10-year median of 40.82)
GF Value™: ¥40.43 vs. price of ¥32.68 (19.2% below fair value)
Industry Position: 233.8% above the Medical Devices & Instruments median (#106 of 814)
No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score
Get the complete analysis for SHSE:603658
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603658 has been successfully added to your 
